Mutation hot spots for clinical pathogenicity across the SLC6 transporter family

Abstract

Genetic mutations of the Solute Carrier 6 (SLC6) family can lead to a diversity of clinal syndromes, such as creatine deficiency. Studying the impact of genetic mutations at the SLC6 family level is valuable not only for their medical significance but also for their conserved sequence and structural features. Within this work, we aim to link the disease-related mutations to their clinical significance from protein-protein interactions (PPIs) perspective, addressing how particular mutations may affect these critical interaction hotspots. In this study, we integrated both curated mutation data from previous work and predictive output from AlphaMissense to examine the entire SLC6 family. The mutations were mapped both onto the sequences and structures of SLC6 transporters. Thereby, a clustering of pathogenic mutations appeared on the surface regions that are likely involved in PPIs. After modeling complexes of SLC6s with potential shared interactors, we assessed these models overall and interface quality. By analyzing the complex interfaces together with the pathogenic mutations, we identified specific hotspots in the interfaces enriched with pathogenic mutations. In-depth examinations of selected PPIs offered insights into how particular mutations may affect these critical interaction hotspots. The hotspots were identified on the ECL3 and ECL4. For instance, Thr394Lys in SLC6A8 was found in the model interfaces, supported by experimental data showing the significant enrichment of the mutated proteins in the ER. Understanding these mutation hotspots can shed light on the broader structure-function relationships of SLC6 transporters and encourage therapeutic interventions targeting protein-protein interactions affected by pathogenic mutations.